Atrial fibrillation following intravenous zolendronic acid for osteoporosis.

Suppr

超能文献

作者信息

Konsta Maria, Bournia Vasiliki-Kalliopi, Dania Vasiliki, Iliopoulos Alexios

机构信息

Department of Rheumatology Veterans Administration Hospital (NIMTS) Athens, Greece

出版信息

J Clin Rheumatol. 2014 Jun;20(4):239-40. doi: 10.1097/RHU.0000000000000114.

DOI:10.1097/RHU.0000000000000114

PMID:24847757

Abstract

摘要

相似文献

Atrial fibrillation following intravenous zolendronic acid for osteoporosis.

J Clin Rheumatol. 2014 Jun;20(4):239-40. doi: 10.1097/RHU.0000000000000114.

[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

MMW Fortschr Med. 2009 Mar 5;151(10):7.

[Osteoporosis and bisphosphonates].

Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. doi: 10.1056/NEJMc071514.

A once-yearly IV bisphosphonate for osteoporosis.

Obstet Gynecol. 2008 May;111(5):1208-9. doi: 10.1097/01.AOG.0000313748.64874.e8.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5.

Consultation corner. Bone loss drug gives users a break.

Johns Hopkins Med Lett Health After 50. 2007 Dec;19(10):6.

Boning up on osteoporosis medications.

Johns Hopkins Med Lett Health After 50. 2010 May;22(3):1-2, 7.

To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.

Duke Med Health News. 2014 Mar;20(3):1-2.

引用本文的文献

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis.

Osteoporos Int. 2016 Dec;27(12):3543-3547. doi: 10.1007/s00198-016-3684-6. Epub 2016 Jun 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Atrial fibrillation following intravenous zolendronic acid for osteoporosis.

J Clin Rheumatol. 2014 Jun;20(4):239-40. doi: 10.1097/RHU.0000000000000114.

[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

MMW Fortschr Med. 2009 Mar 5;151(10):7.

[Osteoporosis and bisphosphonates].

Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. doi: 10.1056/NEJMc071514.

A once-yearly IV bisphosphonate for osteoporosis.

Obstet Gynecol. 2008 May;111(5):1208-9. doi: 10.1097/01.AOG.0000313748.64874.e8.

Yearly zoledronic acid in postmenopausal osteoporosis.

N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5.

Consultation corner. Bone loss drug gives users a break.

Johns Hopkins Med Lett Health After 50. 2007 Dec;19(10):6.

Boning up on osteoporosis medications.

Johns Hopkins Med Lett Health After 50. 2010 May;22(3):1-2, 7.

To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.

Duke Med Health News. 2014 Mar;20(3):1-2.

引用本文的文献

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis.

Osteoporos Int. 2016 Dec;27(12):3543-3547. doi: 10.1007/s00198-016-3684-6. Epub 2016 Jun 25.